Lingdi Zhao

807 total citations
55 papers, 518 citations indexed

About

Lingdi Zhao is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Lingdi Zhao has authored 55 papers receiving a total of 518 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 18 papers in Immunology. Recurrent topics in Lingdi Zhao's work include Cancer Immunotherapy and Biomarkers (25 papers), Immune Cell Function and Interaction (12 papers) and CAR-T cell therapy research (11 papers). Lingdi Zhao is often cited by papers focused on Cancer Immunotherapy and Biomarkers (25 papers), Immune Cell Function and Interaction (12 papers) and CAR-T cell therapy research (11 papers). Lingdi Zhao collaborates with scholars based in China, United States and India. Lingdi Zhao's co-authors include Quanli Gao, Yonghao Yang, Tiepeng Li, Zibing Wang, Yong Zhang, Yongping Song, Xiaomin Fu, Wei Li, Yiman Shang and Lu Han and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Science of The Total Environment.

In The Last Decade

Lingdi Zhao

52 papers receiving 515 citations

Peers

Lingdi Zhao
Shannon Zhang United States
Kailun Fei China
Florencia G. Jalikis United States
Éléonore De Guillebon France
Luisa Chocarro Spain
Sumbal Arooj China
Gesa Schuebbe Germany
Ainara Soria Spain
Charlée Nardin France
Feifei Na China
Shannon Zhang United States
Lingdi Zhao
Citations per year, relative to Lingdi Zhao Lingdi Zhao (= 1×) peers Shannon Zhang

Countries citing papers authored by Lingdi Zhao

Since Specialization
Citations

This map shows the geographic impact of Lingdi Zhao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lingdi Zhao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lingdi Zhao more than expected).

Fields of papers citing papers by Lingdi Zhao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lingdi Zhao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lingdi Zhao. The network helps show where Lingdi Zhao may publish in the future.

Co-authorship network of co-authors of Lingdi Zhao

This figure shows the co-authorship network connecting the top 25 collaborators of Lingdi Zhao. A scholar is included among the top collaborators of Lingdi Zhao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lingdi Zhao. Lingdi Zhao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Yong, Chaoji Zhang, Peng Qin, et al.. (2025). Impact of Tregs on tumor regression in locally advanced G/GEJ cancer patients undergoing neoadjuvant chemoimmunotherapy. Scientific Reports. 15(1). 28995–28995. 1 indexed citations
2.
Xu, Benling, Tingjie Wang, Peng Qin, et al.. (2025). The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis. Scientific Reports. 15(1). 17450–17450. 1 indexed citations
3.
Fu, Xiaomin, et al.. (2024). Combination therapy using low‐dose anlotinib and immune checkpoint inhibitors for extensive‐stage small cell lung cancer. SHILAP Revista de lepidopterología. 3(6). e155–e155. 2 indexed citations
4.
5.
Liu, Xiao, et al.. (2024). Neoadjuvant chemoimmunotherapy in locally advanced gastric or gastroesophageal junction adenocarcinoma. Frontiers in Oncology. 14. 1342162–1342162. 2 indexed citations
6.
Fu, Xiaomin, Peng Qin, Yong Zhang, et al.. (2023). The inter-link of ageing, cancer and immunity: findings from real-world retrospective study. Immunity & Ageing. 20(1). 75–75. 9 indexed citations
7.
Fu, Qiang, Lingdi Zhao, Xiaomin Fu, et al.. (2022). Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma. The Oncologist. 27(6). e463–e470. 9 indexed citations
8.
9.
Peng, Ling, Bicheng Zhang, Brian G. Till, et al.. (2022). Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced Malignancies. Frontiers in Immunology. 13. 882172–882172. 4 indexed citations
10.
Li, Tiepeng, et al.. (2021). Case Report: Afatinib-Induced Interstitial Pneumonia: Experiences and Lessons From Two Patients. Frontiers in Pharmacology. 12. 698447–698447.
11.
Han, Lu, Jian Zhou, Linlin Li, et al.. (2021). Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies. Cancer Biology and Medicine. 18(-). 0–0. 5 indexed citations
12.
Xing, Wenqun, Lingdi Zhao, Xiaomin Fu, et al.. (2020). A phase II, single-centre trial of neoadjuvant toripalimab plus chemotherapy in locally advanced esophageal squamous cell carcinoma. Journal of Thoracic Disease. 12(11). 6861–6867. 18 indexed citations
13.
Zhao, Lingdi, et al.. (2020). Chemotherapy Reverses Anti-PD-1 Resistance in One Patient With Advanced Non-small Lung Cell Cancer. Frontiers in Oncology. 10. 507–507. 3 indexed citations
14.
Li, Wei, Linping Xu, Yaomei Wang, et al.. (2017). Efficacy of Tumor-Infiltrating Lymphocytes Combined with IFN-α in Chinese Resected Stage III Malignant Melanoma. Journal of Immunology Research. 2017. 1–8. 9 indexed citations
15.
Li, Wei, Yaomei Wang, Daniel B. Kellner, et al.. (2016). Efficacy of RetroNectin-activated cytokine-induced killer cell therapy in the treatment of advanced hepatocelluar carcinoma. Oncology Letters. 12(1). 707–714. 11 indexed citations
16.
Gao, Quanli, Lingdi Zhao, Wei Li, et al.. (2015). Angiogenesis inhibitors rechallenge in patients with advanced non-small-cell lung cancer: a pooled analysis of randomized controlled trials. OncoTargets and Therapy. 8. 2775–2775. 9 indexed citations
17.
Li, Wei, Yaomei Wang, Lingdi Zhao, et al.. (2015). Efficacy of RetroNectin-Activated Cytokine-Induced Killer Cell Therapy in Metastatic Brain Tumor Patients. Oncology Research and Treatment. 38(4). 160–165. 10 indexed citations
18.
Wang, Shuai, Xiaohong Han, Xingsheng Hu, et al.. (2014). Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients. Clinica Chimica Acta. 430. 63–70. 44 indexed citations
19.
Wang, Zibing, Yong Zhang, Yuqing Liu, et al.. (2013). Association of Myeloid-derived Suppressor Cells and Efficacy of Cytokine-induced Killer Cell Immunotherapy in Metastatic Renal Cell Carcinoma Patients. Journal of Immunotherapy. 37(1). 43–50. 40 indexed citations
20.
Han, Xiaohong, Li Ma, Lingdi Zhao, et al.. (2012). Predictive factors for inadequate stem cell mobilization in Chinese patients with NHL and HL: 14‐year experience of a single‐center study. Journal of Clinical Apheresis. 27(2). 64–74. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shannon Zhang Breakdown of academic impact, for papers by Kailun Fei Breakdown of academic impact, for papers by Florencia G. Jalikis Breakdown of academic impact, for papers by Éléonore De Guillebon Breakdown of academic impact, for papers by Luisa Chocarro Breakdown of academic impact, for papers by Sumbal Arooj Breakdown of academic impact, for papers by Gesa Schuebbe Breakdown of academic impact, for papers by Ainara Soria Breakdown of academic impact, for papers by Charlée Nardin Breakdown of academic impact, for papers by Feifei Na
Rankless by CCL
2026